Navigation Links
Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
Date:6/24/2009

Study Published in Annals of Internal Medicine

CHERRY HILL, N.J., June 24 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, announced today that red yeast rice, an ingredient contained in Cinnechol, one of the Company's primary supplement products, has been recently proven to decrease levels of low-density lipoprotein, or LDL cholesterol, in dyslipidemic patients. LDL cholesterol is known more informally as "bad" cholesterol. Red yeast rice, which has been used in Ayurvedic medicine and China as a dietary supplement for centuries, contains a compound (monacolin K) that is identical in chemical composition to lovastatin, a commonly prescribed cholesterol-lowering drug.

A recent study titled "Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial," led by cardiologists Dr. David Becker and Dr. Ram Gordon and published in the Annals of Internal Medicine, showed that a diet and exercise regimen that included red yeast rice reduced LDL cholesterol by an average of 27.3%, compared to 5.7% for the control group. Moreover, the study showed that red yeast rice can decrease LDL cholesterol without increasing pain levels.

"Many synthetic statins have been derived from red yeast rice and other naturally occurring phytochemicals," stated Robert Bowker, co-inventor of Cinnechol and President of Knock-Out Technologies, Ltd., a wholly owned subsidiary of Nuvilex. "Red yeast rice, among others, is a bona fide naturally occurring statin. Cinnechol--along with diet and exercise--can help individuals maintain normal cholesterol levels and promote cardiovascular health."

Cinnechol, which contains red yeast rice extract as well as a blend of other ingredients known to improve cardiovascular function (including niacin and guggul gum extract), may provide a natural alternative for those who have high cholesterol and are intolerant of, or elect not to take, statin drugs. Cinnechol can be purchased online by visiting www.cinnechol.com.

"Red yeast rice has now been more thoroughly researched and recognized as an important tool for safely normalizing blood lipids, especially LDL cholesterol," reported Cinnechol co-inventor Steven Kushner, Ph.D. "Cinnechol, by combining Red Yeast Rice with several cardiovascular beneficial synergists, also helps promote healthy total cholesterol levels, improved HDL (beneficial cholesterol) levels, and better blood viscosity."

About Cinnechol

Cinnechol, an ingestible capsule made of all-natural ingredients, is manufactured and sold by Cinnechol, Inc. (a wholly owned subsidiary of Nuvilex, Inc.). Cinnechol is designed to help maintain normal cholesterol levels and to support normal cardiovascular function. Cinnechol, along with a healthy diet and exercise regimen, is intended to serve as a dietary supplement to help individuals manage numerous cardiovascular and metabolic disorders (including dyslipidemia, hypertension, hypoglycemia, and hyperglycemia).

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
2. Nuvilex Featured in Wall Street Reporter Interview
3. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
4. Nuvilex Launches Video Marketing Campaign
5. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
6. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
7. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
8. Nuvilex, Inc. Announces Monthly Investor Conference Call
9. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
10. Nuvilex, Inc. Announces Investor Conference Call and Open House
11. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. ... Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at ... Maisel, founder of Retina Group of New York , is a Board ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... comprehensive treatment for eating disorders, is opening a brand new child and adolescent ... ages 8-17 and their families with even more specialized eating disorder treatment and ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... On May 23rd during the National Eye Institute’s “Healthy Vision Month”, Sharon ... honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon Kleyne is ... the Nile to fill their red clay pots with life-sustaining water.” Said Ashram co-founder ...
(Date:5/26/2016)... ... 2016 , ... Saint Francis Hospital & Medical Center has ... have paid off. Since implementation of these efforts, surgical errors and readmissions ... patient experiences and reduce costly complications. Since implementation in 2011, safety efforts have: ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
Breaking Medicine Technology: